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A B S T R A C T
Oxcarbazepine (OXC) is generally accepted as a drug without risk of severe drug-induced hepatotoxicity, but accord-
ing to recently reported pharmacovigilance data this statement has been challenged. However, in the literature there have
been no reports of acute OXC-induced hepatotoxicity without systemic manifestations of Drug Rash with Eosinophilia
and Systemic Symptoms (DRESS) syndrome. We present a female with seizures one month after delivery who had bor-
derline elevated liver enzymes prior to the initiation of OXC treatment. Two weeks after introducing OXC, highly ele-
vated liver enzymes were found. After discontinuation of OXC the enzymes continued to rise for another week, and after-
ward gradually decreased. The causal relationship with OXC intake was determined to be highly probable. Two years
later, the transitory elevation of liver enzymes was observed during the treatment of acute tonsilopharingitis with amo-
xicillin + clavulanic acid. The repeated elevation of liver enzymes related to use of different drugs might indicate pa-
tient`s susceptibility for drug induced liver injuries. We suggest that monitoring of liver function tests would be clinically
rational for early detection of acute OXC-induced liver hepatotoxicity in the patients with clinical and/or laboratory fea-
tures which might be interpreted as possible risk factors of the increased susceptibility to drug induced liver injuries.
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Introduction
Hepatotoxicity of the antiepileptic drugs (AEDs) is a
complex phenomenon with a wide spectrum of clinical
manifestations ranging from a mild increase of serum liver
enzyme levels to a potentially fatal drug-induced liver failu-
re1. Albeit rare, these side effects can be life threatening, and
so it is of paramount importance to recognize them early1,2.
Oxcarbazepine (OXC) is generally accepted as a drug
with a lower incidence of adverse side effects than carba-
mazepine (CBZ). In the Summary of Product Character-
istics (SPC) of OXC it is reported that, according to the
Council for International Organizations of Medical Sci-
ences (CIOMS) classification system, the incidence of
hepatitis is very rare (<1/10000), so that the liver func-
tion testing is recommended only when liver disease is
suspected3. However, according to recently reported phar-
macovigilance data, it has been proposed that low fre-
quency of the OXC-induced Drug Rash with Eosinophila
and Systemic Symptoms (DRESS) syndrome, which in-
cludes hepatotoxicity, mainly reflects a less frequent use
of OXC in comparison to CBZ4. Except for DRESS syn-
drome5, in a recent study the case of OXC-induced liver
adenoma has been reported6. To our knowledge, there
have been no reports of acute OXC-induced hepatotoxicity.
The objective of our manuscript is to present a young
female patient with severe OXC-induced hepatotoxicity
and to discuss possible mechanisms that could have
caused the observed hepatotoxicity.
Case Report
The patient is a twenty-three year old woman who ex-
perienced several seizures one month post partum. OXC
was initiated for seizure control.
281
Received for publication February 7, 2010
Family history was positive for epilepsy in a paternal
uncle. The patient had febrile seizures at the ages of 6
and 18 months, for which she was treated with pheno-
barbital. She had no other risk factors for epilepsy. She
was hospitalized for uterine bleed in the first trimester of
her pregnancy and treated with dydrogesterone for 10
days. She gained 20 kg during pregnancy, while her base-
line weight was 53 kg. The borderline alanine amino-
transferase (ALT) elevation was reported during preg-
nancy. One month after delivery, the patient experienced
several partial complex seizures with oral automatisms
and change in consciousness. A diagnosis of localization
related epilepsy was established based on clinical de-
scription and EEG changes. A routine EEG revealed
non-specific abnormalities in the baseline activity with
minor left frontotemporal changes. The EEG following
sleep deprivation confirmed left frontotemporal irrita-
tive changes. The brain MRI scan was unremarkable.
She was not breastfeeding and OXC was prescribed at
300 mg twice a day (19th April 2007). Previously made
baseline laboratory studies were normal except for bor-
derline elevated aspartate transaminase (AST) and gam-
ma glutamyl transpeptidase (GGT) (13th April). Because
of these slight abnormalities, a laboratory checkup was
made on May 4th and revealed significantly elevated liver
enzymes (Table 1). The patient did not report these labo-
ratory abnormalities until 10 days later, when she was
subsequently hospitalized. She reported fatigue and ap-
petite loss; she was afebrile and her physical and neuro-
logical examinations did not reveal any clinically signifi-
cant abnormalities. She was not taking any concomitant
medication and an OXC-induced liver injury was sus-
pected. On May 15th, OXC was discontinued and therapy
with gabapentin was initiated. After three days mainte-
nance dose of gabapentin (900 mg/day) was achieved.
However, liver enzyme abnormalities continued for an-
other six days, followed by a gradual improvement, as it
is presented in Table 1.
The findings of bilirubin, coagulopathy testing, and
proteinogram were normal. The blood count did not re-
veal an eosinophilia; only slight lymphocytosis was pres-
ent (WBC 5.28 ´ 109/L, lymphocytes 46.6%). The ultra-
sound of the liver showed hyperechogenic liver paren-
chyma with a normal-caliber common bile duct without
evidence of obstruction or other biliary tract abnormali-
ties. The patient had mildly elevated total cholesterol
(5.41 mmol/L). Additional studies were performed to rule
out preexisting liver conditions. The patient had elevated
anti-HBs (615 IU/L) as a result of previous vaccination
against Hepatitis B, as well as other negative markers for
hepatitis B and hepatitis C. Epstein Barr virus (EBV)
and cytomegalovirus (CMV) serology revealed a previous
EBV (VCA IgG 142 AU/mL; EBNA IgG > 200 AU/mL)
and CMV (IgG 1.3 IU/mL) infection. Additional testing
excluded liver metabolic abnormalities (Fe, UIBC, TIBC,
serum ferritin level, transferrin saturation; serum Cu/
24-hour urine; serum ceruloplasmin; Alpha 1 – antitry-
psin) as well as autoimmune hepatitis. Subsequently, the
good clinical remission was achieved and she was under
regular follow-up by epileptologist and gastroenterolo-
gist. Two years later, in the May of the 2009 the transi-
tory elevation of liver enzymes was observed again during
the treatment of acute tonsilopharingitis with amoxi-
cillin + clavulanic acid (maximum upper limits of normal
values (ULN) were: AST 1.6, ALT 3.7, GGT 2.3).
Discussion
It is widely regarded that OXC and CBZ have a simi-
lar efficacy, but that OXC is better tolerated. OXC can in-
duce mild to moderate liver enzyme abnormalities, but
not a clinically significant hepatotoxicity7. However, sim-
ilar to the experience with other AEDs, the evaluation of
rare adverse effects requires the years-long post-market-
ing monitoring of a large number of patients. According
to the recently reported pharmacovigilance data, the
safety of OXC in regards to liver function has been
challenged4.
Based on clinical presentation and diagnostic workup,
we conclude that the reported patient had an OXC-in-
duced liver injury. Additional diagnostic studies have
confirmed a previous CMV and EBV infection, and ex-
cluded hepatitis B and C, metabolic liver abnormalities
(Wilson’s disease, hemochromatosis, alpha-1-antitrypsin
deficiency, and autoimmune hepatitis). According to the
CIOMS scale8,9, causal relationship between the OXC in-
take and hepatotoxicity would be »probable« (score 8).
Further association with pregnancy, as one of the risk
factor for drug induced liver injury, would increase this
causal relationship in our patient to »highly probable or
definite« (score 9).
It is reported that a hepatocellular lesion may repre-
sent an additional signal needed to initiate the process of a
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TABLE 1
DYNAMICS OF AST, ALT, GGT AND ALP THAT ARE EXPRESSED
IN UPPER LIMITS OF NORMAL (ULN) VALUES
Date AST ALT GGT ALP
April 13th 1.2 1.0 1.2
April 19th OXC introduced
May 7th 5.2 6.6 6.8
May 14th 5.0 8.9 6.1 2.0
May 15th OXC switched to GBP
May 16th 4.8 8.3 10.0 2.2
May 19th 10.8 13.0 9.9
May 21st 11.6 17.3 10.4
May 24th 5.1 12.5 9.9 1.8
May 28th 4.0 9.6 10.4 2.0
July 11th 1.5 3.7 3.5
Sept 10th 0.7 1.0 2.3 1.0
AST – aspartate transaminase, ALT – alanine transaminase,
GGT – glutamyl transpeptidase, ALP – alcal phosphatase
hypersensitivity reaction10. Our patient had borderline
values of laboratory liver tests prior to OXC treatment
and we believe that these abnormalities might indicate
slight hepatic dysfunction. It is known that hepatic me-
tabolism can be altered during pregnancy11,12, but a mini-
mal elevation of liver enzymes might have also been due
to liver steatosis, associated with 20 kg weight gain during
pregnancy. We are aware that idiosyncratic type of drug
induced liver injuries cannot be predicted and that routine
check of liver tests after starting antiepileptic drug ther-
apy has not been considered to be cost-effective13. How-
ever, based on the clinical course of the reported patient, it
seems that the association between the hypothetical risk
factors (previous pregnancy, abnormalities of liver en-
zymes) might have not been interpreted as accidental, and
we believe that monitoring of liver enzymes after intro-
ducing of OXC in this case was clinically rational.
The fact that our patient also had transitory elevation
of liver enzymes during the treatment with amoxicillin +
clavulanic acid might be interpreted as our patient’s sus-
ceptibility for drug induced liver injuries.In regard to
possible pathophysiological mechanisms leading to OXC-
-induced idiosyncratic hepatotoxicity, it is important to
emphasize structural similarities between CBZ and OXC.
While the mechanisms of idiosyncratic reactions are not
yet elucidated, it is assumed that they are caused by reac-
tive metabolites, which are generated in small amounts
during the drug metabolism. In susceptible individuals
these metabolites are generated at increased rate and/or
are not effectively cleared. Reactive metabolites may
cause hepatotoxicity directly or by inducing immunologic
reactions1.
It has been hypothesized that the reactive CBZ metab-
olite which induces hepatotoxicity is an arene oxide, or,
more specifically, an unstable and reactive CBZ epoxide14.
However, some new studies have not confirmed this hy-
pothesis, in part because of the difficulties in achieving a
definitive proof of the arene-oxide due to its high insta-
bility15. Furst and Utrecht identified some other CBZ
metabolites as reactive: 9-acridine carboxaldehyde, imino-
stilbene and iminoquinone16. In addition, based on the
structural similarity, they proposed 9-hydroxymethyl-10-
-carbamoyl-acridan (9-acridan), acridine and acridone to
be potentially reactive17. Recently, in the sera of patients
treated with OXC monotherapy and those with CBZ mono-
therapy, shared metabolites 9-acridan and 3-hydroxycar-
bamazepine were detected2. Figure 1 shows metabolic
routes leading to formation of potentially reactive metab-
olite 9-acridan during biotransformation of CBZ and OXC.
An additional reactive metabolite iminoquinone can be
generated from 3-hydroxycar-bamazepine2.
In conclusion, we would like to emphasize that OXC
and CBZ have some shared metabolites, a few of which
are reactive. Those reactive metabolites, by analogy with
CBZ hepatotoxicity, could also induce OXC hepatotoxi-
city. Possible common mechanisms of adverse reactions
for these two drugs are also supported by similar side ef-
fect profile and observed skin cross-reactivity18.
To our knowledge, this is the first time that the acute
OXC-induced hepatotoxicity is reported without syste-
mic symptoms of DRESS syndrome. We suggest that rou-
tine monitoring of liver function tests would be indicated
for early detection of acute OXC-induced liver hepatoto-
xicity in the patients with clinical and/or laboratory fea-
tures which might be interpreted as possible risk factors
for drug induced liver injuries (e.g. previously known
borderline values of laboratory liver tests, pregnancy,
liver steatosis, elevation of liver enzymes during the
treatment with other drugs etc.).
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Fig. 1. Formation of 9-acridan during metabolism of CBZ and OXC (modified from Breton et al., 2005). The figure presents only CBZ
and OXC metabolic pathways that take part in the generation of 9-acridan; other biotransformation pathways of CBZ and OXC are not
presented here. Abbreviations: MHD – 10-hydroxy-10,11-dihydro-carbamazepine, E-CBZ – carbamazepine-10,11-epoxide, DHD – 10,11-
-trans-dihydroxy-carbamazepine, 9-acridan-9-hydroxymethyl-10-carbamoyl acridan.
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AKUTNA HEPATOTOKSI^NOST INDUCIRANA OKSKARBAZEPINOM U OSOBE
PODLO@NE RAZVOJU JETRENOG O[TE]ENJA UZROKOVANOG LIJEKOVIMA
S A @ E T A K
Okskarbazepin (OXC) je op}enito prihva}en kao lijek koji nije rizi~an za razvoj te{kog jetrenog o{te}enja uzroko-
vanog lijekovima, me|utim navedena je tvrdnja osporena nedavno objavljenim podacima farmakovigilancije. Prema
na{im saznanjima, u literaturi nema objavljenih slu~ajeva akutne okskarbazepinom inducirane hepatotoksi~nosti bez
sistemskih manifestacija DRESS sindroma (Drug Rash with Eosinophilia and Systemic Symptoms). U prikazu slu~aja,
radi se o `eni koja je 6 tjedana nakon poroda imala nekoliko epilepti~kih napadaja zbog ~ega joj je propisan okskar-
bazepin. Prije zapo~etog lije~enja zabilje`ene su grani~no povi{ene vrijednosti jetrenih enzima. Nakon dva tjedna pro-
vo|enja terapije okskarbazepinom na|ene su izrazito povi{ene vrijednosti jetrenih enzima koje su nastavile rasti jo{
tjedan dana nakon prekida terapije, a tada su se po~ele postupno smanjivati. Prema CIOMS/RUCAM skali uzro~na
povezanost s primjenom okskarbazepina je ocijenjena kao »visoko vjerojatna«. Dvije godine kasnije, za vrijeme lije~enja
akutnog tonzilofaringitisa kombinacijom amoksicilina i klavulonske kiseline, zamije}eno tako|er je prolazno povi{enje
jetrenih enzima. Opetovano povi{enje jetrenih enzima povezano uz primjenu drugih lijekova moglo bi upu}ivati na
podlo`nost razvoju jetrenog o{te}enja uzrokovanog lijekovima. Smatramo da je monitoriranje testova jetrene funkcije
klini~ki racionalno u ranoj detekciji akutne okskarbazepinom inducirane hepatotoksi~nosti u svih pacijenata s klini-
~kim i/ili laboratorijskim obilje`jima koja bi mogla biti interpretirana kao mogu}i rizi~ni ~imbenici za pove}anu pod-
lo`nost razvoju jetrenog o{te}enja uzrokovanog lijekovima.
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